Demographics, outcomes, and risk factors for patients with sarcoma and COVID-19: A CCC19-registry based retrospective cohort study Journal Article
| Authors: | Wagner, M. J.; Hennessy, C.; Beeghly, A.; French, B.; Shah, D. P.; Croessmann, S.; Vilar-Compte, D.; Ruiz-Garcia, E.; Ingham, M.; Schwartz, G. K.; Painter, C. A.; Chugh, R.; Fecher, L.; Park, C.; Zamulko, O.; Trent, J. C.; Subbiah, V.; Khaki, A. R.; Tachiki, L.; Nakasone, E. S.; Loggers, E. T.; Labaki, C.; Saliby, R. M.; McKay, R. R.; Ajmera, A.; Griffiths, E. A.; Puzanov, I.; Tap, W. D.; Hwang, C.; Tejwani, S.; Jhawar, S. R.; Hayes-Lattin, B.; Wulff-Burchfield, E.; Kasi, A.; Reuben, D. Y.; Nagaraj, G.; Joshi, M.; Polimera, H.; Kulkarni, A. A.; Esfahani, K.; Kwon, D. H.; Paoluzzi, L.; Bilen, M. A.; Durbin, E. B.; Grivas, P.; Warner, J. L.; Davis, E. J.; on behalf of the COVID-19 and Cancer Consortium |
| Article Title: | Demographics, outcomes, and risk factors for patients with sarcoma and COVID-19: A CCC19-registry based retrospective cohort study |
| Abstract: | Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. Results: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity. Conclusions: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death. © 2022 by the authors. |
| Keywords: | osteosarcoma; adult; controlled study; treatment response; aged; major clinical study; gastrointestinal stromal tumor; disease association; oxygen therapy; cohort analysis; creatinine; creatinine blood level; vasculotropin inhibitor; retrospective study; risk factor; histology; age; protein tyrosine kinase inhibitor; ewing sarcoma; sarcoma; intensive care unit; lung metastasis; hospitalization; disease severity; soft tissue sarcoma; lactate dehydrogenase; leukocyte count; cancer classification; rhabdomyosarcoma; anthracycline; lactate dehydrogenase blood level; infection risk; artificial ventilation; d dimer; clinical outcome; demographics; mortality rate; absolute lymphocyte count; time to treatment; human; male; female; article; median survival time; absolute neutrophil count; mortality risk; ecog performance status; immunological antineoplastic agent; coronavirus disease 2019; covid-19; sars-cov-2; ccc19; cardiovascular system sarcoma |
| Journal Title: | Cancers |
| Volume: | 14 |
| Issue: | 17 |
| ISSN: | 2072-6694 |
| Publisher: | MDPI |
| Date Published: | 2022-09-01 |
| Start Page: | 4334 |
| Language: | English |
| DOI: | 10.3390/cancers14174334 |
| PROVIDER: | scopus |
| PMCID: | PMC9454925 |
| PUBMED: | 36077869 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 October 2022 -- Source: Scopus |
